临床生化检验指标在COVID-19疾病进展及治疗中的应用评价  

Evaluation of clinical biochemical indexes in the progression and treatment of COVID-19

作　　者：贺勇[1] 干伟[1] 张玫[1] 聂鑫[1] 宋昊岚[1] 何訸[1] 赵艳华[1] 梁珊珊 李小玲[1] 李贵星[1] HE Yong;GAN Wei;ZHANG Mei;NIE Xin;SONG Haolan;HE He;ZHAO Yanhua;LIANG Shanshan;LI Xiaoling;LI Guixing(Department of Laboratory Medicine,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China)

机构地区：[1]四川大学华西医院实验医学科,四川成都610041

出　　处：《国际检验医学杂志》2020年第8期906-909,共4页International Journal of Laboratory Medicine

摘　　要：新型冠状病毒(SARS-CoV-2)引发新型冠状病毒肺炎(COVID-19)的流行,该病为新发的传染病,其来源、病理机制等诸多方面尚未完全清楚。该病的诊断、变化及治疗评价需要检验提供重要的依据,该病在发生、发展过程中会引起肺、肾脏、肝脏、心脏等多器官损伤,而这些器官是否受损及受损的程度依赖临床检验的结果。该文重点阐述COVID-19发生、发展及治疗过程中合理选择实验室检查项目及检查结果的临床意义,以期为该病的准确治疗、疾病进展、疗效评估等提供理论依据。A novel coronavirus called severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has caused the epidemic of corona virus disease 2019(COVID-19).The disease is a newly emerging infectious disease,and its source,pathological mechanism and other aspects are not fully understood.Laboratory results provide an important basis for its diagnosis,change and treatment evaluation.It will cause damage to multiple organs such as lung,kidney,liver,heart in the diease occurrence and development.Whether this organ is damaged or not and the level of damage depends on results of laboratory examination.This paper focuses on the clinical significance of rational selection of laboratory examination items and examination results in the development and treatment of COVID-19,so as to provide a theoretical basis for the accurate treatment,disease progression and efficacy evaluation.

关 键 词：新型冠状病毒 新型冠状病毒肺炎 临床生化检验指标 

分 类 号：R563.1[医药卫生—呼吸系统]